 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12345678910111213...2021» |
- || Trintellix (vortioxetine) / Lundbeck, Takeda, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Review, Journal: Interventions for the management of long covid (post-covid condition): living systematic review. (Pubmed Central) - Nov 28, 2024
Moderate certainty evidence suggests that CBT and physical and mental health rehabilitation probably improve symptoms of long covid.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical, Journal: A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19. (Pubmed Central) - Nov 25, 2024
P2
It is therefore perhaps not surprising that no differences between treatments were observed in the primary endpoint or in pre-specified secondary endpoints among participants with mild-to-moderate COVID-19. However, the results of the exploratory post hoc analysis showing that participants in the leronlimab group had greater improvement in NEWS2 assessment compared to placebo provided a suggestion that leronlimab may be associated with a lower likelihood of people with mild-to-moderate COVID-19 progressing to more severe disease and needs to be confirmed in other appropriately designed clinical trials.
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Journal: FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques. (Pubmed Central) - Sep 26, 2024
Further, a single dose of leronlimab-PLS led to complete CCR5 receptor occupancy in mothers and newborns for almost a month after birth. These findings support the optimization of FcRn interactions in mAb therapies designed for administration during pregnancy.
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Preclinical, Journal: Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: Synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis. (Pubmed Central) - Sep 5, 2024
Apart from that, the MD simulation study also disclosed stable binding interactions of DH-18 and MMP-2 along with crucial interactions with active site amino acid residues namely His120, Glu121, His124, His130, Pro140, and Tyr142. In a nutshell, this study highlighted the importance of biphenylsulfonamide-based novel and promising MMP-2 inhibitors to open up a new avenue for potential therapy against CML.
- PGT121 / Gilead, IAVI, VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques (Cusco Ballroom/Channel 4) - Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_223;
The results of this study suggest that the combination of ART, bNAbs, and CCR5 blockade via Leronlimab synergize in an undefined mechanism to prevent further seeding of of the reservoir early after infection, and may even permanently reduce it. Further studies are warranted to study this combinatorial effect in more detail.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical, Journal: Is preexisting inflamed jaw marrow a "hidden" co-morbidity affecting outcomes of COVID-19 infections? - Clinical comparative study. (Pubmed Central) - Jun 19, 2024
The authors propose a new approach to containment of the COVID-19 cytokine storm by a prophylactic focus for future viral-related pandemics, which may be early surgical clean-up of CCL5/RANTES expression sources in the FDOJ/AIOJ areas, thus diminishing a possible pre-sensitization of CCR5. A more complete dental examination includes trans-alveolar ultrasono-graphy (TAU) for hidden FDOJ/AIOJ lesions.
- LS-variant anti-CCR5 monoclonal antibody provides long-lasting protection against intrarectal SHIV acquisition in rhesus macaques (Poster board: 028) - May 2, 2024 - Abstract #AIDS2024AIDS_1071;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia (Poster board: 027) - May 2, 2024 - Abstract #AIDS2024AIDS_1054;
The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Leronlimab (Twitter) - Jun 24, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Funny you don’t mention anything about Ccr5 blocking with Pro-140, even though you are on their SAB… (Twitter) - Apr 16, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
What about leronlimab? (Twitter) - Mar 15, 2023
- ||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Trial completion, Enrollment change: Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis (clinicaltrials.gov) - Mar 1, 2023
P2, N=87, Completed, Sponsor: CytoDyn, Inc.
If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference. Active, not recruiting --> Completed | N=60 --> 87
- |||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
I would choose leronlimab, but the FDA/NIH only have eyes for Big Pharma. Saving COVID lives since March 2020. The genocide continues. Day 918. (Twitter) - Feb 27, 2023
- Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
New P2 trial, Combination therapy, Metastases: Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 16, 2023
P2, N=0, Withdrawn, Sponsor: CytoDyn, Inc.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
It seems that your promotion on PRO-140 is a big failure?! (Twitter) - Feb 8, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Leronlimab is owned by a company that is tangled up with regulators due to some shady actions. Rather than wait years for these problems to be sorted out, Patterson moved on to a different CCR5 antagonist. We're in a pandemic and time is precious. (Twitter) - Jan 15, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Free Leronlimab #freeleronlimab #savelives #leronlimab (Twitter) - Jan 14, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
All the studies and trials on Leronlimab are all now in doubt because of there nefarious ex CEO. Leronlimab most likely is a great Mab but unfortunately it was not in the proper hands like @bruce13 what a shame! (Twitter) - Jan 14, 2023
- ||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
FDA event: @joerogan could your research help get Leronlimab approved. When will we see change in the FDA? @Jim_Jordan @GovRonDeSantis @RonJohnsonWI (Twitter) - Jan 14, 2023
- ||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical: Leronlimab, ccr5 antagonist, needs to be approved. Yes, Nader was bad, either way the drug would have saved lives and helped so many patients. (Twitter) - Jan 13, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Watch bruce patterson talk abt #leronlimab at TED https://t.co/mV58r0AYyP (Twitter) - Jan 13, 2023
- ||| Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Adverse events: Leronlimab is a very safe drug with virtually no side effects unlike Maraviroc (Twitter) - Jan 13, 2023
- ||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
P2 data: #leronlimab covid severe critical phase 2 trial cd12. (Twitter) - Jan 13, 2023
- |||| Selzentry (maraviroc) / ViiV Healthcare, Tollovir (NLC-V-01) / Todos Medical, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Preprint: Yes #Maraviroc is a #CCR5 inhibitor. Love to hear the rationale on why its better suited in #LongCovid over #leronlimab & #tollovir which we hear are also a CCR5 antagonists. Curious if read preprint on #galectin3 & perhaps its potential in #PASC #COVID19 https://t.co/GHlWtO1OyO (Twitter) - Jan 12, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Bogus, you know Leronlimab is the ultimate choice, come out and say it! (Twitter) - Jan 12, 2023
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
dr scott kelly is gone. it's time you promoted leronlimab and go back to Cytodyn (Twitter) - Jan 1, 2023
- |||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
https://t.co/hJLzl5iMu0 $cydy #leronlimab #cytodyn #COVID19 @CytoDyn @TomLandstreet @brucep13 (Twitter) - Dec 27, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
@brucep13 Can you explain what is going on with #Leronlimab? https://t.co/gMvE1wXVNL (Twitter) - Dec 23, 2022
- |||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Monotherapy: CytoDyn Inc announces major discovery for its flagship drug leronlimab as a monotherapy $CYDY @brucep13 You’re on the clock as well https://t.co/SUFSvo4uwh https://t.co/5237LTnMwm (Twitter) - Dec 22, 2022
- ||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical: NaDDer Pourhassan @npourhassan1 and his mother in law leaving the hospital after Leronlimab cured her stroke, cancer, emphysema and ED all at once. That’s @brucep13 looking for his lost paperwork in the back. $CYDY @CytoDyn (Twitter) - Dec 21, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Break out Leronlimab now! (Twitter) - Nov 28, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Leronlimab for the tool box? (Twitter) - Nov 22, 2022
- | Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Journal: Editorial: CCR5: A receptor at the center stage in infection. (Pubmed Central) - Nov 12, 2022
Active, not recruiting --> Completed | N=60 --> 87 No abstract available
- ||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical: When will you lobby for Leronlimab, you know you need this tool for helping patients. (Twitter) - Nov 9, 2022
- ||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical: "Not Big Pharma." -- Not mom-and-pop. "The study, which was funded by Leronlimab maker CytoDyn Inc. and conducted by researchers either employed by or serving as consultants to the company, was published online April 22 in the peer reviewed journal Clinical Infectious Diseases." (Twitter) - Nov 7, 2022
- Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
LERONLIMAB IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: RESULTS FROM NASH01 METABOLIC AND IMMUNOMODULATORY MECHANISMS OF ACTION () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1225;
CCR5 is believed to dimerize with itself or with other chemokine receptors, and these heterodimers may be capable of signaling via the natural ligands of either receptor. Our previously published data suggests that treatment with leronlimab stabilizes CCR5 cell surface levels.
- Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
EFFICACY AND SAFETY OF LERONLIMAB IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS: KEY BIOMARKER RESULTS FROM NASH01 () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1146;
These exploratory results show leronlimab significantly reduced mean change in PDFF, cT1, and key inflammatory markers from baseline to week 14 for the 350 mg group and for the moderate and severe fibro-inflammation subgroups. The mechanism of action for leronlimab suggests to be multifactorial, involving VCAM, CCL2, CCL3, CCL11, and CCL18 in addition to competitive binding of CCR5 effecting metabolic and fibro-inflammatory parameters with implications for systemic reductions in vascular permeability, arterial stiffness, and oxidative stress.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical: Why are you still promoting the efficacy of Leronlimab on your website? https://t.co/qaYiOILve1 (Twitter) - Oct 21, 2022
- Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Clinical experience and outcomes of critically-ill patients in a tertiary hospital who received Leronlimab for compassionate use as an adjunct therapy for COVID-19 () - Oct 15, 2022 - Abstract #APSR2022APSR_616;
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Leronlimab is coming, will be freed from the grips of deception. #savelives #leronlimab (Twitter) - Oct 14, 2022
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Journal: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. (Pubmed Central) - Oct 5, 2022
P2
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants...Clinical Trials Registration. NCT04678830.
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
I’d like to hear your opinion on Leronlimab. Thank you. (Twitter) - Oct 1, 2022
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
#Leronlimab, Katie 🙏 (Twitter) - Sep 30, 2022
- ||| Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Dr, #maraviroc and #leronlimab were effective working together in #hiv trials years ago. So so You think they might be helpfull in #longcovid too? (Twitter) - Sep 21, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Any news on the Leronlimab front? it also showed some promise in a small Ph 2 (Twitter) - Sep 13, 2022
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
#leronlimab. find them a partner and get the shady @US_FDA off their back. (Twitter) - Sep 12, 2022
- || Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Incelldx is mired in self-interest. Inflated recovery rates from their protocol, the whole leronlimab saga (convenient maraviroc is suddenly the answer eh), ignoring the large number of people who don't get better on maraviroc/statin. Red flags all over the shop. (Twitter) - Sep 10, 2022
- || Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Those unquestioningly following Patterson seem blind to his self-interest in all of this. Remember leronlimab? Funny how maraviroc, the other CCR5 inhibitor, became the magic PASC cure, despite many PASC sufferers not getting better on it. But sure, they must not have PASC... 🤦 (Twitter) - Sep 10, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
#CytoDyn World-Wide Sales for #LERONLIMAB was .27m USD in Q4 2022 https://t.co/FpaITde5P9 (Twitter) - Sep 7, 2022
- || Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Zero human trials. Leronlimab still on the shelf Bobby. Failing. (Twitter) - Aug 31, 2022